You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameClozapine
Accession NumberDB00363  (APRD00470)
TypeSmall Molecule
GroupsApproved
DescriptionA tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. [PubChem]
Structure
Thumb
Synonyms
Clozapin
Clozapina
Clozapine
Clozapinum
External Identifiers
  • HF 1854
  • LX 100-129
  • W 108
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aa-clozapinetablet25 mgoralAa Pharma Inc2004-01-27Not applicableCanada
Aa-clozapinetablet100 mgoralAa Pharma Inc2004-01-27Not applicableCanada
Auro-clozapinetablet25 mgoralAuro Pharma IncNot applicableNot applicableCanada
Auro-clozapinetablet50 mgoralAuro Pharma IncNot applicableNot applicableCanada
Auro-clozapinetablet100 mgoralAuro Pharma IncNot applicableNot applicableCanada
Auro-clozapinetablet200 mgoralAuro Pharma IncNot applicableNot applicableCanada
Clozapinetablet, orally disintegrating25 mg/1oralTeva Pharmaceuticals USA Inc2012-08-30Not applicableUs
Clozapinetablet, orally disintegrating150 mg/1oralTeva Pharmaceuticals USA Inc2015-05-05Not applicableUs
Clozapinetablet, orally disintegrating100 mg/1oralTeva Pharmaceuticals USA Inc2012-08-30Not applicableUs
Clozapinetablet, orally disintegrating200 mg/1oralTeva Pharmaceuticals USA Inc2015-05-05Not applicableUs
Clozapinetablet, orally disintegrating12.5 mg/1oralTeva Pharmaceuticals USA Inc2012-08-30Not applicableUs
Clozariltablet25 mg/1oralNovartis Pharmaceuticals Corporation1989-09-30Not applicableUs
Clozariltablet100 mgoralHls Therapeutics Inc1991-12-31Not applicableCanada
Clozariltablet100 mg/1oralNovartis Pharmaceuticals Corporation1989-09-30Not applicableUs
Clozariltablet25 mgoralHls Therapeutics Inc1991-12-31Not applicableCanada
Clozariltablet100 mg/1oralCardinal Health1989-09-30Not applicableUs
Clozariltablet25 mg/1oralTYA Pharmaceuticals1989-09-30Not applicableUs
Fazaclotablet, orally disintegrating12.5 mg/1oralJazz Pharmaceuticals, Inc.2007-07-01Not applicableUs
Fazaclotablet, orally disintegrating200 mg/1oralJazz Pharmaceuticals, Inc.2010-07-09Not applicableUs
Fazaclotablet, orally disintegrating25 mg/1oralJazz Pharmaceuticals, Inc.2008-06-01Not applicableUs
Fazaclotablet, orally disintegrating100 mg/1oralJazz Pharmaceuticals, Inc.2008-06-01Not applicableUs
Fazaclotablet, orally disintegrating150 mg/1oralJazz Pharmaceuticals, Inc.2010-07-09Not applicableUs
Gen-clozapinetablet25 mgoralMylan Pharmaceuticals Ulc2003-03-14Not applicableCanada
Gen-clozapinetablet100 mgoralMylan Pharmaceuticals Ulc2003-03-14Not applicableCanada
Gen-clozapinetablet50 mgoralMylan Pharmaceuticals Ulc2008-02-05Not applicableCanada
Gen-clozapinesuspension50 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Gen-clozapinetablet200 mgoralMylan Pharmaceuticals Ulc2008-02-05Not applicableCanada
PMS-clozapinetablet25 mgoralPharmascience Inc2003-03-052011-01-20Canada
PMS-clozapinetablet100 mgoralPharmascience Inc2003-03-052011-01-20Canada
Sandoz Clozapinetablet25 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Clozapinetablet100 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Versaclozsuspension50 mg/mLoralJazz Pharmaceuticals, Inc.2013-02-15Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Clozapinetablet200 mg/1oralMylan Pharmaceuticals Inc.2010-04-20Not applicableUs
Clozapinetablet100 mg/1oralCardinal Health2010-02-12Not applicableUs
Clozapinetablet25 mg/1oralTeva Pharmaceuticals USA Inc2007-05-10Not applicableUs
Clozapinetablet100 mg/1oralActavis Pharma, Inc.2015-12-22Not applicableUs
Clozapinetablet25 mg/1oralAccord Healthcare Inc.2016-03-01Not applicableUs
Clozapinetablet25 mg/1oralMylan Pharmaceuticals Inc.1999-07-08Not applicableUs
Clozapinetablet, orally disintegrating25 mg/1oralMylan Pharmaceuticals Inc.2015-11-02Not applicableUs
Clozapinetablet50 mg/1oralTeva Pharmaceuticals USA Inc2007-03-19Not applicableUs
Clozapinetablet50 mg/1oralSun Pharmaceutical Industries, Inc.2005-08-19Not applicableUs
Clozapinetablet200 mg/1oralMylan Institutional Inc.2010-07-06Not applicableUs
Clozapinetablet100 mg/1oralAccord Healthcare Inc.2016-03-01Not applicableUs
Clozapinetablet100 mg/1oralMylan Pharmaceuticals Inc.1999-07-08Not applicableUs
Clozapinetablet, orally disintegrating100 mg/1oralMylan Pharmaceuticals Inc.2015-11-02Not applicableUs
Clozapinetablet200 mg/1oralTeva Pharmaceuticals USA Inc2007-05-15Not applicableUs
Clozapinetablet25 mg/1oralSun Pharmaceutical Industries, Inc.2002-11-15Not applicableUs
Clozapinetablet25 mg/1oralMylan Institutional Inc.1999-11-15Not applicableUs
Clozapinetablet100 mg/1oralAvera Mc Kennan Hospital2015-08-12Not applicableUs
Clozapinetablet50 mg/1oralMylan Pharmaceuticals Inc.2010-04-20Not applicableUs
Clozapinetablet25 mg/1oralActavis Pharma, Inc.2015-12-22Not applicableUs
Clozapinetablet100 mg/1oralTeva Pharmaceuticals USA Inc2009-09-18Not applicableUs
Clozapinetablet100 mg/1oralSun Pharmaceutical Industries, Inc.2002-11-15Not applicableUs
Clozapinetablet100 mg/1oralMylan Institutional Inc.1999-11-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AzaleptineArpimed
ClomentPharmaplan
ClonexAdeka
ClopinEast West
ClopineDouglas
ClopsinePsicofarma
ClorazemRemedica
LanoleptLannacher
LapenaxNovartis
LeponexNovartis
LoduxRider
LozapinTorrent
LuftenPharos
MezapinPanbiotic
RefractCrescent
RefraxolAC Farma
SensipinBeximco
SequaxIvax
SizopinSun
SizoprilMeprofarm
SyclopBrown & Burk Phils
SyzopinPsyco Remedies
TanylNovamed
UspenYu Sheng
ZapenPsipharma
ZapeniaIncepta
ZapineTaiwan Biotech
ZiprocTorrent
ZopinPsychotropics India
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIJ60AR2IKIC
CAS number5786-21-0
WeightAverage: 326.823
Monoisotopic: 326.129824335
Chemical FormulaC18H19ClN4
InChI KeyQZUDBNBUXVUHMW-UHFFFAOYSA-N
InChI
InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3
IUPAC Name
6-chloro-10-(4-methylpiperazin-1-yl)-2,9-diazatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaene
SMILES
CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzodiazepines. These are compounds containing a dibenzodiazepine moiety, which consists of two benzene connected by a diazepine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub ClassDibenzodiazepines
Direct ParentDibenzodiazepines
Alternative Parents
Substituents
  • Dibenzodiazepine
  • 1,4-benzodiazepine
  • N-alkylpiperazine
  • N-methylpiperazine
  • Chlorobenzene
  • Imidolactam
  • Benzenoid
  • Piperazine
  • 1,4-diazinane
  • Aryl halide
  • Aryl chloride
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Secondary amine
  • Carboxylic acid amidine
  • Amidine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor use in patients with treatment-resistant schizophrenia.
PharmacodynamicsClozapine is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Clozapine is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors. Clozapine acts as an antagonist at other receptors, but with lower potency. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other therapeutic and side effects of Clozapine. Clozapine's antagonism of muscarinic M1-5 receptors may explain its anticholinergic effects. Clozapine's antagonism of histamine H1 receptors may explain the somnolence observed with this drug. Clozapine's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug.
Mechanism of actionClozapine's antipsychotic action is likely mediated through a combination of antogistic effects at D2 receptors in the mesolimbic pathway and 5-HT2A receptors in the frontal cortex. D2 antagonism relieves positive symptoms while 5-HT2A antagonism alleviates negative symptoms.
Related Articles
AbsorptionRapid and almost complete
Volume of distributionNot Available
Protein binding97% (bound to serum proteins)
Metabolism

Hepatic

SubstrateEnzymesProduct
Clozapine
NorclozapineDetails
Clozapine
Clozapine N-oxideDetails
Clozapine
Clozapine glucuronideDetails
Route of eliminationApproximately 50% of the administered dose is excreted in the urine and 30% in the feces.
Half life8 hours (range 4-12 hours)
ClearanceNot Available
ToxicityClozapine carries a black-box warning for agranulocytosis.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3
Gene symbol: GNB3
UniProt: P16520
rs5443 Not AvailableTT alleleSchizophrenia patients taking this drug more more weight than patients with at least one rs5443(c) allele16141801
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9904
Blood Brain Barrier+0.9614
Caco-2 permeable+0.6151
P-glycoprotein substrateSubstrate0.8684
P-glycoprotein inhibitor IInhibitor0.6791
P-glycoprotein inhibitor IIInhibitor0.7407
Renal organic cation transporterInhibitor0.8049
CYP450 2C9 substrateNon-substrate0.7509
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.6088
CYP450 1A2 substrateInhibitor0.5722
CYP450 2C9 inhibitorNon-inhibitor0.9432
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9137
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.571
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9106
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.0838 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8189
hERG inhibition (predictor II)Inhibitor0.7164
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Azur pharma international iii ltd
  • Caraco pharmaceutical laboratories ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Par pharmaceutical
  • Sandoz inc
  • Novartis pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
Tabletoral200 mg/1
Tabletoral50 mg/1
Tablet, orally disintegratingoral100 mg/1
Tablet, orally disintegratingoral12.5 mg/1
Tablet, orally disintegratingoral150 mg/1
Tablet, orally disintegratingoral200 mg/1
Tablet, orally disintegratingoral25 mg/1
Tabletoral100 mg/1
Tabletoral25 mg/1
Suspensionoral50 mg
Tabletoral100 mg
Tabletoral200 mg
Tabletoral25 mg
Tabletoral50 mg
Suspensionoral50 mg/mL
Prices
Unit descriptionCostUnit
Fazaclo 100 mg odt6.55USD tablet
Clozapine 200 mg tablet6.32USD tablet
Clozaril 100 mg tablet5.84USD tablet
Clozapine 100 mg tablet3.33USD tablet
Apo-Clozapine 100 mg Tablet2.77USD tablet
Gen-Clozapine 100 mg Tablet2.77USD tablet
Fazaclo 25 mg odt2.4USD tablet
Fazaclo 25 mg tablet2.19USD tablet
Clozaril 25 mg tablet1.96USD tablet
Fazaclo 12.5 mg odt1.79USD tablet
Clozapine 50 mg tablet1.65USD tablet
Clozapine 25 mg tablet1.28USD tablet
Apo-Clozapine 25 mg Tablet0.69USD tablet
Gen-Clozapine 25 mg Tablet0.69USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5178878 No1993-01-122010-01-12Us
US6024981 No1998-04-092018-04-09Us
US6106861 No1997-12-052017-12-05Us
US6221392 No1998-04-092018-04-09Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point183-184 °CPhysProp
water solubility11.8 mg/LNot Available
logP3.23HANSCH,C ET AL. (1995)
pKa7.5EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.186 mg/mLALOGPS
logP3.67ALOGPS
logP3.4ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)15.9ChemAxon
pKa (Strongest Basic)7.35ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area30.87 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity97.36 m3·mol-1ChemAxon
Polarizability35.77 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Schmutz, J. and Hunziker, F.; US. Patent 3,539,573; November 10, 1970 .

US3539573
General References
  1. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA: Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993 Jul 15;329(3):162-7. [PubMed:8515788 ]
  2. Vaddadi KS, Soosai E, Vaddadi G: Low blood selenium concentrations in schizophrenic patients on clozapine. Br J Clin Pharmacol. 2003 Mar;55(3):307-9. [PubMed:12630982 ]
  3. Naheed M, Green B: Focus on clozapine. Curr Med Res Opin. 2001;17(3):223-9. [PubMed:11900316 ]
  4. Lane HY, Chang YC, Chang WH, Lin SK, Tseng YT, Jann MW: Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry. 1999 Jan;60(1):36-40. [PubMed:10074876 ]
External Links
ATC CodesN05AH02
AHFS Codes
  • 28:16.08.04
PDB EntriesNot Available
FDA labelDownload (89.8 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineClozapine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineClozapine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Clozapine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Clozapine is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Clozapine can be increased when it is combined with Abiraterone.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Clozapine.
AcepromazineThe risk or severity of adverse effects can be increased when Clozapine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Clozapine is combined with Aceprometazine.
AcetaminophenThe serum concentration of Clozapine can be increased when it is combined with Acetaminophen.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Clozapine.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Clozapine.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Clozapine.
adipiplonThe risk or severity of adverse effects can be increased when Clozapine is combined with adipiplon.
AfatinibThe serum concentration of Clozapine can be increased when it is combined with Afatinib.
AgomelatineThe risk or severity of adverse effects can be increased when Clozapine is combined with Agomelatine.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Clozapine.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Clozapine.
AlbendazoleThe serum concentration of Clozapine can be increased when it is combined with Albendazole.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Clozapine.
AldosteroneThe serum concentration of Clozapine can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Clozapine can be increased when it is combined with Alectinib.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Clozapine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Clozapine is combined with Alfaxalone.
AlfentanilThe serum concentration of Clozapine can be increased when it is combined with Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Clozapine is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Clozapine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Clozapine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Clozapine.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Clozapine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Clozapine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Clozapine is combined with Alprazolam.
AlprenololThe metabolism of Alprenolol can be decreased when combined with Clozapine.
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Clozapine.
AmantadineAmantadine may increase the QTc-prolonging activities of Clozapine.
Aminohippuric acidThe serum concentration of Clozapine can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Clozapine.
AmiodaroneClozapine may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe serum concentration of Clozapine can be decreased when it is combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Clozapine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Clozapine.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Clozapine.
AmlodipineThe serum concentration of Clozapine can be increased when it is combined with Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Clozapine is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Clozapine is combined with Amperozide.
AmphetamineClozapine may decrease the stimulatory activities of Amphetamine.
AmprenavirThe serum concentration of Clozapine can be decreased when it is combined with Amprenavir.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Clozapine.
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Clozapine.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Clozapine.
AnagrelideClozapine may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Clozapine.
ApomorphineApomorphine may increase the QTc-prolonging activities of Clozapine.
AprepitantThe serum concentration of Clozapine can be increased when it is combined with Aprepitant.
AprindineThe metabolism of Aprindine can be decreased when combined with Clozapine.
ArformoterolArformoterol may increase the QTc-prolonging activities of Clozapine.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Clozapine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Clozapine.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Clozapine.
ArmodafinilThe metabolism of Clozapine can be decreased when combined with Armodafinil.
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Clozapine.
Arsenic trioxideClozapine may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherClozapine may increase the QTc-prolonging activities of Artemether.
ArtemetherThe metabolism of Clozapine can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Articaine.
AsenapineClozapine may increase the QTc-prolonging activities of Asenapine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Clozapine.
AstemizoleThe serum concentration of Clozapine can be increased when it is combined with Astemizole.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Clozapine.
AtazanavirAtazanavir may increase the QTc-prolonging activities of Clozapine.
AtenololThe serum concentration of Clozapine can be increased when it is combined with Atenolol.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Clozapine.
AtomoxetineThe metabolism of Atomoxetine can be decreased when combined with Clozapine.
AtorvastatinThe serum concentration of Clozapine can be increased when it is combined with Atorvastatin.
AzacitidineThe risk or severity of adverse effects can be increased when Azacitidine is combined with Clozapine.
AzaperoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Azaperone.
AzelastineClozapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe serum concentration of Clozapine can be increased when it is combined with Azelastine.
AzithromycinClozapine may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe serum concentration of Clozapine can be increased when it is combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Clozapine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Clozapine is combined with Barbital.
BedaquilineClozapine may increase the QTc-prolonging activities of Bedaquiline.
BelinostatThe risk or severity of adverse effects can be increased when Belinostat is combined with Clozapine.
BendamustineThe risk or severity of adverse effects can be increased when Bendamustine is combined with Clozapine.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Clozapine.
BenzocaineThe serum concentration of Clozapine can be increased when it is combined with Benzocaine.
BenzocaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Benzocaine.
BenzphetamineClozapine may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Clozapine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Clozapine.
BepridilThe serum concentration of Clozapine can be increased when it is combined with Bepridil.
BepridilThe metabolism of Bepridil can be decreased when combined with Clozapine.
BetaxololThe metabolism of Clozapine can be decreased when combined with Betaxolol.
BevacizumabThe risk or severity of adverse effects can be increased when Bevacizumab is combined with Clozapine.
BexaroteneThe risk or severity of adverse effects can be increased when Bexarotene is combined with Clozapine.
BiperidenThe serum concentration of Clozapine can be increased when it is combined with Biperiden.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Clozapine.
BlinatumomabThe risk or severity of adverse effects can be increased when Blinatumomab is combined with Clozapine.
BoceprevirThe metabolism of Clozapine can be decreased when combined with Boceprevir.
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Clozapine.
BortezomibThe metabolism of Bortezomib can be decreased when combined with Clozapine.
BosentanThe serum concentration of Clozapine can be decreased when it is combined with Bosentan.
BosutinibThe risk or severity of adverse effects can be increased when Bosutinib is combined with Clozapine.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Clozapine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Clozapine.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clozapine.
BrimonidineThe risk or severity of adverse effects can be increased when Clozapine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Clozapine is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clozapine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Clozapine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Clozapine.
BrotizolamThe risk or severity of adverse effects can be increased when Clozapine is combined with Brotizolam.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Clozapine.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Clozapine.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Clozapine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clozapine.
BuprenorphineThe serum concentration of Clozapine can be increased when it is combined with Buprenorphine.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Clozapine.
BupropionThe metabolism of Bupropion can be decreased when combined with Clozapine.
BuserelinBuserelin may increase the QTc-prolonging activities of Clozapine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Clozapine.
BuspironeThe metabolism of Buspirone can be decreased when combined with Clozapine.
BusulfanThe risk or severity of adverse effects can be increased when Busulfan is combined with Clozapine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clozapine.
ButacaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Clozapine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Clozapine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Clozapine is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Clozapine is combined with Butorphanol.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Clozapine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Clozapine.
CaffeineThe serum concentration of Clozapine can be increased when it is combined with Caffeine.
CaffeineThe metabolism of Caffeine can be decreased when combined with Clozapine.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Clozapine.
CanagliflozinThe serum concentration of Clozapine can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Clozapine can be increased when it is combined with Candesartan.
CapecitabineThe risk or severity of adverse effects can be increased when Capecitabine is combined with Clozapine.
CaptoprilThe serum concentration of Clozapine can be increased when it is combined with Captopril.
CaptoprilThe metabolism of Captopril can be decreased when combined with Clozapine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Clozapine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Clozapine is combined with Carbinoxamine.
CarboplatinThe risk or severity of adverse effects can be increased when Carboplatin is combined with Clozapine.
CarfentanilThe risk or severity of adverse effects can be increased when Clozapine is combined with Carfentanil.
CarfilzomibThe risk or severity of adverse effects can be increased when Carfilzomib is combined with Clozapine.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Clozapine.
CarisoprodolThe risk or severity of adverse effects can be increased when Clozapine is combined with Carisoprodol.
CarmustineThe risk or severity of adverse effects can be increased when Carmustine is combined with Clozapine.
CarteololThe metabolism of Carteolol can be decreased when combined with Clozapine.
CarvedilolThe serum concentration of Clozapine can be increased when it is combined with Carvedilol.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Clozapine.
CaspofunginThe serum concentration of Clozapine can be increased when it is combined with Caspofungin.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Clozapine.
CelecoxibThe metabolism of Clozapine can be decreased when combined with Celecoxib.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Clozapine.
CeritinibThe serum concentration of Clozapine can be increased when it is combined with Ceritinib.
CeritinibClozapine may increase the QTc-prolonging activities of Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Clozapine is combined with Cetirizine.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Clozapine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Clozapine is combined with Chloral hydrate.
ChlorambucilThe risk or severity of adverse effects can be increased when Chlorambucil is combined with Clozapine.
ChloramphenicolThe risk or severity of adverse effects can be increased when Chloramphenicol is combined with Clozapine.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Clozapine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Clozapine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Chloroprocaine.
ChloroquineThe serum concentration of Clozapine can be increased when it is combined with Chloroquine.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Clozapine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Clozapine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Clozapine.
ChlorphentermineClozapine may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe serum concentration of Clozapine can be increased when it is combined with Chlorpromazine.
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Clozapine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Clozapine.
ChlorpropamideThe serum concentration of Clozapine can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Clozapine can be increased when it is combined with Chlorprothixene.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Clozapine is combined with Chlorprothixene.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Clozapine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Clozapine.
CholecalciferolThe metabolism of Clozapine can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Clozapine can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Clozapine can be decreased when it is combined with Cholic Acid.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Clozapine.
CilazaprilThe serum concentration of Clozapine can be increased when it is combined with Cilazapril.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Clozapine.
CimetidineThe serum concentration of Clozapine can be decreased when it is combined with Cimetidine.
CinacalcetThe metabolism of Clozapine can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Cinchocaine.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Clozapine.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Clozapine.
CisaprideClozapine may increase the QTc-prolonging activities of Cisapride.
CisplatinThe risk or severity of adverse effects can be increased when Cisplatin is combined with Clozapine.
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Clozapine.
CitalopramClozapine may increase the QTc-prolonging activities of Citalopram.
CladribineThe risk or severity of adverse effects can be increased when Cladribine is combined with Clozapine.
ClarithromycinClozapine may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe serum concentration of Clozapine can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Clozapine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Clozapine is combined with Clemastine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Clozapine.
ClidiniumThe risk or severity of adverse effects can be increased when Clozapine is combined with Clidinium.
ClobazamThe metabolism of Clozapine can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Clozapine is combined with Clobazam.
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Clozapine.
ClofazimineThe serum concentration of Clozapine can be increased when it is combined with Clofazimine.
clomethiazoleThe risk or severity of adverse effects can be increased when Clozapine is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Clozapine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clozapine is combined with Clonazepam.
ClonidineThe metabolism of Clonidine can be decreased when combined with Clozapine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Clozapine.
ClopidogrelThe metabolism of Clozapine can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Clozapine is combined with Clorazepate.
ClotrimazoleThe metabolism of Clozapine can be decreased when combined with Clotrimazole.
CobicistatThe serum concentration of Clozapine can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Cocaine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Clozapine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Clozapine.
ColchicineThe serum concentration of Clozapine can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Clozapine can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Clozapine can be increased when it is combined with Conivaptan.
CrizotinibClozapine may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Clozapine can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Clozapine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clozapine.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Clozapine.
CyclophosphamideThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Clozapine.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Clozapine.
CyclosporineThe metabolism of Clozapine can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Clozapine is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Clozapine can be decreased when it is combined with Cyproterone acetate.
CytarabineThe risk or severity of adverse effects can be increased when Cytarabine is combined with Clozapine.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Clozapine.
DacarbazineThe risk or severity of adverse effects can be increased when Dacarbazine is combined with Clozapine.
DaclatasvirThe serum concentration of Clozapine can be increased when it is combined with Daclatasvir.
DactinomycinThe risk or severity of adverse effects can be increased when Dactinomycin is combined with Clozapine.
DantroleneThe risk or severity of adverse effects can be increased when Clozapine is combined with Dantrolene.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Clozapine.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clozapine.
DapoxetineThe serum concentration of Clozapine can be increased when it is combined with Dapoxetine.
DapoxetineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dapoxetine.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Clozapine.
DarunavirThe serum concentration of Clozapine can be increased when it is combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Clozapine.
DasatinibThe risk or severity of adverse effects can be increased when Dasatinib is combined with Clozapine.
DaunorubicinThe risk or severity of adverse effects can be increased when Daunorubicin is combined with Clozapine.
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Clozapine.
DecitabineThe risk or severity of adverse effects can be increased when Decitabine is combined with Clozapine.
DeferasiroxThe serum concentration of Clozapine can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Clozapine.
DelavirdineThe metabolism of Clozapine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Clozapine is combined with deramciclane.
DesfluraneDesflurane may increase the QTc-prolonging activities of Clozapine.
DesfluraneThe risk or severity of adverse effects can be increased when Clozapine is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Clozapine.
DesipramineThe metabolism of Desipramine can be decreased when combined with Clozapine.
DesloratadineThe serum concentration of Clozapine can be increased when it is combined with Desloratadine.
DesloratadineThe risk or severity of adverse effects can be increased when Clozapine is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Clozapine.
DetomidineThe risk or severity of adverse effects can be increased when Clozapine is combined with Detomidine.
DexamethasoneThe serum concentration of Clozapine can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dexbrompheniramine.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Clozapine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dexmedetomidine.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Clozapine.
DexrazoxaneThe risk or severity of adverse effects can be increased when Dexrazoxane is combined with Clozapine.
DextroamphetamineClozapine may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Clozapine.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Clozapine.
DextromoramideThe risk or severity of adverse effects can be increased when Clozapine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Clozapine is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Clozapine is combined with Diazepam.
DiclofenacThe serum concentration of Clozapine can be increased when it is combined with Diclofenac.
DifenoxinThe risk or severity of adverse effects can be increased when Clozapine is combined with Difenoxin.
DigoxinThe serum concentration of Clozapine can be decreased when it is combined with Digoxin.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Clozapine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clozapine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Clozapine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dihydromorphine.
DiltiazemThe metabolism of Clozapine can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Clozapine is combined with Dimenhydrinate.
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Clozapine.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Clozapine.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Clozapine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Clozapine is combined with Diphenoxylate.
DipyridamoleThe serum concentration of Clozapine can be increased when it is combined with Dipyridamole.
DisopyramideClozapine may increase the QTc-prolonging activities of Disopyramide.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Clozapine.
DofetilideClozapine may increase the QTc-prolonging activities of Dofetilide.
DolasetronDolasetron may increase the QTc-prolonging activities of Clozapine.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Clozapine.
DomperidoneClozapine may increase the QTc-prolonging activities of Domperidone.
DonepezilThe metabolism of Donepezil can be decreased when combined with Clozapine.
DopamineThe metabolism of Dopamine can be decreased when combined with Clozapine.
DoramectinThe risk or severity of adverse effects can be increased when Clozapine is combined with Doramectin.
DoxazosinThe serum concentration of Clozapine can be increased when it is combined with Doxazosin.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Clozapine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Clozapine.
DoxepinThe metabolism of Doxepin can be decreased when combined with Clozapine.
DoxorubicinThe risk or severity of adverse effects can be increased when Doxorubicin is combined with Clozapine.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Clozapine.
DoxycyclineThe metabolism of Clozapine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Clozapine.
DoxylamineThe risk or severity of adverse effects can be increased when Clozapine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Clozapine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Clozapine.
DronedaroneClozapine may increase the QTc-prolonging activities of Dronedarone.
DronedaroneThe metabolism of Clozapine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Clozapine is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Clozapine is combined with Drotebanol.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Clozapine.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Clozapine.
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Clozapine.
DyclonineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Clozapine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Clozapine is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Clozapine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Clozapine is combined with Efavirenz.
ElbasvirThe serum concentration of Clozapine can be increased when it is combined with Elbasvir.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Clozapine.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Clozapine.
EliglustatClozapine may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Clozapine can be decreased when combined with Eliglustat.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Clozapine.
EnalaprilThe serum concentration of Clozapine can be increased when it is combined with Enalapril.
EncainideThe metabolism of Encainide can be decreased when combined with Clozapine.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Clozapine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Clozapine.
EntacaponeThe risk or severity of adverse effects can be increased when Clozapine is combined with Entacapone.
EnzalutamideThe serum concentration of Clozapine can be decreased when it is combined with Enzalutamide.
EpinastineThe metabolism of Epinastine can be decreased when combined with Clozapine.
EpirubicinThe risk or severity of adverse effects can be increased when Epirubicin is combined with Clozapine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Clozapine.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Clozapine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Clozapine.
EribulinThe risk or severity of adverse effects can be increased when Eribulin is combined with Clozapine.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Clozapine.
ErythromycinClozapine may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Clozapine can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Clozapine.
EscitalopramClozapine may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Clozapine can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Clozapine.
EsomeprazoleThe metabolism of Clozapine can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Clozapine is combined with Estazolam.
EstramustineThe serum concentration of Clozapine can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Clozapine can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Clozapine can be decreased when it is combined with Estrone.
EszopicloneThe risk or severity of adverse effects can be increased when Clozapine is combined with Eszopiclone.
EthanolClozapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Clozapine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clozapine.
EthosuximideThe risk or severity of adverse effects can be increased when Clozapine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Clozapine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Clozapine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Clozapine is combined with Ethyl loflazepate.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Clozapine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Clozapine.
EtidocaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Clozapine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Clozapine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Clozapine.
EtoperidoneThe serum concentration of Clozapine can be increased when it is combined with Etoperidone.
EtoperidoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Etoperidone.
EtoposideThe risk or severity of adverse effects can be increased when Etoposide is combined with Clozapine.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Clozapine.
EtorphineThe risk or severity of adverse effects can be increased when Clozapine is combined with Etorphine.
EtravirineThe serum concentration of Clozapine can be decreased when it is combined with Etravirine.
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Clozapine.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Clozapine.
EzogabineEzogabine may increase the QTc-prolonging activities of Clozapine.
EzogabineThe risk or severity of adverse effects can be increased when Clozapine is combined with Ezogabine.
FamotidineFamotidine may increase the QTc-prolonging activities of Clozapine.
FelbamateFelbamate may increase the QTc-prolonging activities of Clozapine.
FelbamateThe risk or severity of adverse effects can be increased when Clozapine is combined with Felbamate.
FelodipineThe serum concentration of Clozapine can be increased when it is combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Clozapine is combined with Fencamfamine.
FenfluramineThe serum concentration of Clozapine can be increased when it is combined with Fenfluramine.
FenfluramineThe risk or severity of adverse effects can be increased when Clozapine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Clozapine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clozapine.
FexofenadineThe serum concentration of Clozapine can be increased when it is combined with Fexofenadine.
FexofenadineThe risk or severity of adverse effects can be increased when Clozapine is combined with Fexofenadine.
FidaxomicinThe serum concentration of Clozapine can be increased when it is combined with Fidaxomicin.
FingolimodFingolimod may increase the QTc-prolonging activities of Clozapine.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Clozapine.
FlecainideFlecainide may increase the QTc-prolonging activities of Clozapine.
FlecainideThe metabolism of Flecainide can be decreased when combined with Clozapine.
FlibanserinThe risk or severity of adverse effects can be increased when Clozapine is combined with Flibanserin.
FloxuridineThe risk or severity of adverse effects can be increased when Floxuridine is combined with Clozapine.
FluconazoleFluconazole may increase the QTc-prolonging activities of Clozapine.
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Clozapine.
FludarabineThe risk or severity of adverse effects can be increased when Fludarabine is combined with Clozapine.
FludiazepamThe risk or severity of adverse effects can be increased when Clozapine is combined with Fludiazepam.
FlumazenilThe risk or severity of adverse effects can be increased when Flumazenil is combined with Clozapine.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Clozapine.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Clozapine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Clozapine is combined with Flunitrazepam.
FluorouracilThe risk or severity of adverse effects can be increased when Fluorouracil is combined with Clozapine.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Clozapine.
FluoxetineClozapine may increase the QTc-prolonging activities of Fluoxetine.
FlupentixolClozapine may increase the QTc-prolonging activities of Flupentixol.
FlupentixolThe serum concentration of Clozapine can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Clozapine can be increased when it is combined with Fluphenazine.
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Clozapine.
FlurazepamThe serum concentration of Clozapine can be increased when it is combined with Flurazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Clozapine is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Clozapine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Clozapine is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Clozapine.
FluvoxamineThe risk or severity of adverse effects can be increased when Clozapine is combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Clozapine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Clozapine.
FosamprenavirThe metabolism of Clozapine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Clozapine can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Clozapine.
FosphenytoinThe serum concentration of Clozapine can be decreased when it is combined with Fosphenytoin.
FosphenytoinThe risk or severity of adverse effects can be increased when Clozapine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Clozapine is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Clozapine.
Fusidic AcidThe serum concentration of Clozapine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Clozapine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Clozapine is combined with gabapentin enacarbil.
Gadobenic acidClozapine may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineGalantamine may increase the QTc-prolonging activities of Clozapine.
GalantamineThe metabolism of Galantamine can be decreased when combined with Clozapine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Clozapine is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Clozapine can be increased when it is combined with Gefitinib.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Clozapine.
GemcitabineThe risk or severity of adverse effects can be increased when Gemcitabine is combined with Clozapine.
GemfibrozilThe metabolism of Clozapine can be decreased when combined with Gemfibrozil.
GemifloxacinClozapine may increase the QTc-prolonging activities of Gemifloxacin.
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clozapine.
GenisteinThe serum concentration of Clozapine can be increased when it is combined with Genistein.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Clozapine.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Clozapine.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Clozapine.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Clozapine.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Clozapine.
GlutethimideThe risk or severity of adverse effects can be increased when Clozapine is combined with Glutethimide.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Clozapine.
GlyburideThe serum concentration of Clozapine can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Clozapine can be increased when it is combined with Glycerol.
GoserelinGoserelin may increase the QTc-prolonging activities of Clozapine.
Gramicidin DThe serum concentration of Clozapine can be increased when it is combined with Gramicidin D.
GranisetronGranisetron may increase the QTc-prolonging activities of Clozapine.
GranisetronThe metabolism of Granisetron can be decreased when combined with Clozapine.
GrepafloxacinThe serum concentration of Clozapine can be increased when it is combined with Grepafloxacin.
GuanfacineThe risk or severity of adverse effects can be increased when Clozapine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Clozapine is combined with Halazepam.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Clozapine.
HaloperidolThe serum concentration of Clozapine can be increased when it is combined with Haloperidol.
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Clozapine.
HalothaneThe metabolism of Halothane can be decreased when combined with Clozapine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Clozapine.
HeroinThe risk or severity of adverse effects can be increased when Clozapine is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Clozapine is combined with Hexobarbital.
HistrelinHistrelin may increase the QTc-prolonging activities of Clozapine.
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Clozapine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Clozapine.
HydrocortisoneThe serum concentration of Clozapine can be increased when it is combined with Hydrocortisone.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Clozapine.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Clozapine.
Hydroxyamphetamine hydrobromideClozapine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyureaThe risk or severity of adverse effects can be increased when Hydroxyurea is combined with Clozapine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clozapine.
HydroxyzineThe risk or severity of adverse effects can be increased when Clozapine is combined with Hydroxyzine.
IbandronateIbandronate may increase the QTc-prolonging activities of Clozapine.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clozapine.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Clozapine.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Clozapine.
IbutilideClozapine may increase the QTc-prolonging activities of Ibutilide.
IdarubicinThe risk or severity of adverse effects can be increased when Idarubicin is combined with Clozapine.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Clozapine.
IdelalisibThe serum concentration of Clozapine can be increased when it is combined with Idelalisib.
IfosfamideThe risk or severity of adverse effects can be increased when Ifosfamide is combined with Clozapine.
IloperidoneClozapine may increase the QTc-prolonging activities of Iloperidone.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Clozapine.
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with Clozapine.
ImatinibThe metabolism of Imatinib can be decreased when combined with Clozapine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Clozapine.
ImipramineThe metabolism of Imipramine can be decreased when combined with Clozapine.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Clozapine.
IndalpineThe serum concentration of Clozapine can be increased when it is combined with Indalpine.
IndalpineThe risk or severity of adverse effects can be increased when Clozapine is combined with Indalpine.
IndapamideIndapamide may increase the QTc-prolonging activities of Clozapine.
IndinavirThe serum concentration of Clozapine can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Clozapine can be increased when it is combined with Indomethacin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Clozapine.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Clozapine.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Clozapine.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Clozapine.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Clozapine.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Clozapine.
Interferon alfa-n3The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Clozapine.
Interferon alfacon-1The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Clozapine.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Clozapine.
IrbesartanThe metabolism of Clozapine can be decreased when combined with Irbesartan.
IrinotecanThe risk or severity of adverse effects can be increased when Irinotecan is combined with Clozapine.
IsavuconazoniumThe metabolism of Clozapine can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Clozapine.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Clozapine.
IsofluraneThe risk or severity of adverse effects can be increased when Clozapine is combined with Isoflurane.
IsoniazidThe metabolism of Clozapine can be decreased when combined with Isoniazid.
IsradipineIsradipine may increase the QTc-prolonging activities of Clozapine.
ItraconazoleItraconazole may increase the QTc-prolonging activities of Clozapine.
IvabradineIvabradine may increase the QTc-prolonging activities of Clozapine.
IvacaftorThe serum concentration of Clozapine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Clozapine can be increased when it is combined with Ivermectin.
IxabepiloneThe risk or severity of adverse effects can be increased when Ixabepilone is combined with Clozapine.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Clozapine.
KetamineThe serum concentration of Clozapine can be increased when it is combined with Ketamine.
KetamineThe risk or severity of adverse effects can be increased when Clozapine is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Clozapine is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Ketobemidone.
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Clozapine.
L-PhenylalanineThe risk or severity of adverse effects can be increased when L-Phenylalanine is combined with Clozapine.
LabetalolThe metabolism of Labetalol can be decreased when combined with Clozapine.
LamotrigineThe risk or severity of adverse effects can be increased when Clozapine is combined with Lamotrigine.
LansoprazoleThe serum concentration of Clozapine can be increased when it is combined with Lansoprazole.
LapatinibLapatinib may increase the QTc-prolonging activities of Clozapine.
LeflunomideThe metabolism of Clozapine can be decreased when combined with Leflunomide.
LenalidomideThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Clozapine.
LenvatinibClozapine may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Clozapine.
LevetiracetamThe risk or severity of adverse effects can be increased when Clozapine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Clozapine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Clozapine is combined with Levocetirizine.
LevodopaThe metabolism of Levodopa can be decreased when combined with Clozapine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Clozapine.
LevofloxacinClozapine may increase the QTc-prolonging activities of Levofloxacin.
LevofloxacinThe serum concentration of Clozapine can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Clozapine is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Clozapine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Clozapine is combined with Levorphanol.
LevothyroxineThe serum concentration of Clozapine can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Clozapine can be increased when it is combined with Lidocaine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Clozapine.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Clozapine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Clozapine.
LiothyronineThe serum concentration of Clozapine can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Clozapine can be decreased when it is combined with Liotrix.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Clozapine.
LisdexamfetamineClozapine may decrease the stimulatory activities of Lisdexamfetamine.
LisinoprilThe serum concentration of Clozapine can be increased when it is combined with Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Clozapine.
LithiumLithium may increase the neurotoxic activities of Clozapine.
LithiumThe risk or severity of adverse effects can be increased when Clozapine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Clozapine is combined with Lofentanil.
LomitapideThe serum concentration of Clozapine can be increased when it is combined with Lomitapide.
LomustineThe risk or severity of adverse effects can be increased when Lomustine is combined with Clozapine.
LomustineThe metabolism of Lomustine can be decreased when combined with Clozapine.
LoperamideThe serum concentration of Clozapine can be increased when it is combined with Loperamide.
LoperamideThe metabolism of Loperamide can be decreased when combined with Clozapine.
LopinavirClozapine may increase the QTc-prolonging activities of Lopinavir.
LopinavirThe serum concentration of Clozapine can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Clozapine can be increased when it is combined with Loratadine.
LoratadineThe metabolism of Loratadine can be decreased when combined with Clozapine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Clozapine.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Clozapine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Clozapine.
LosartanThe serum concentration of Clozapine can be increased when it is combined with Losartan.
LovastatinThe metabolism of Clozapine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Clozapine is combined with Lu AA21004.
LuliconazoleThe serum concentration of Clozapine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Clozapine can be decreased when it is combined with Lumacaftor.
LumefantrineClozapine may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Clozapine can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clozapine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Clozapine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Clozapine.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Clozapine.
MebendazoleThe serum concentration of Clozapine can be increased when it is combined with Mebendazole.
MechlorethamineThe risk or severity of adverse effects can be increased when Mechlorethamine is combined with Clozapine.
MeclizineThe risk or severity of adverse effects can be increased when Clozapine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Clozapine is combined with Medetomidine.
MefloquineMefloquine may increase the QTc-prolonging activities of Clozapine.
Megestrol acetateThe serum concentration of Clozapine can be increased when it is combined with Megestrol acetate.
MelatoninThe risk or severity of adverse effects can be increased when Clozapine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Melperone.
MelphalanThe risk or severity of adverse effects can be increased when Melphalan is combined with Clozapine.
MephentermineClozapine may decrease the stimulatory activities of Mephentermine.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Clozapine.
MepivacaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Mepivacaine.
MeprobamateThe serum concentration of Clozapine can be increased when it is combined with Meprobamate.
MeprobamateThe risk or severity of adverse effects can be increased when Clozapine is combined with Meprobamate.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Clozapine.
MercaptopurineThe risk or severity of adverse effects can be increased when Mercaptopurine is combined with Clozapine.
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Clozapine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Clozapine.
MetaxaloneThe risk or severity of adverse effects can be increased when Clozapine is combined with Metaxalone.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Clozapine.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Clozapine.
MethadoneThe metabolism of Methadone can be decreased when combined with Clozapine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Clozapine is combined with Methadyl Acetate.
MethamphetamineClozapine may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Clozapine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Methaqualone.
MethimazoleThe risk or severity of adverse effects can be increased when Methimazole is combined with Clozapine.
MethocarbamolThe risk or severity of adverse effects can be increased when Clozapine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Clozapine is combined with Methohexital.
MethotrexateThe risk or severity of adverse effects can be increased when Methotrexate is combined with Clozapine.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Clozapine.
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Clozapine.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Clozapine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Clozapine.
MethsuximideThe risk or severity of adverse effects can be increased when Clozapine is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Clozapine is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Clozapine is combined with Methylphenobarbital.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Clozapine.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Clozapine.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Clozapine.
MetoprololThe serum concentration of Clozapine can be increased when it is combined with Metoprolol.
MetoprololThe metabolism of Metoprolol can be decreased when combined with Clozapine.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Clozapine.
MetyrosineClozapine may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Clozapine.
MexiletineThe serum concentration of Clozapine can be increased when it is combined with Mexiletine.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Clozapine.
MianserinThe metabolism of Mianserin can be decreased when combined with Clozapine.
MibefradilThe serum concentration of Clozapine can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Clozapine can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Clozapine can be decreased when it is combined with Midazolam.
MidazolamThe risk or severity of adverse effects can be increased when Clozapine is combined with Midazolam.
MifepristoneMifepristone may increase the QTc-prolonging activities of Clozapine.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Clozapine.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Clozapine.
MilnacipranThe risk or severity of adverse effects can be increased when Clozapine is combined with Milnacipran.
MinaprineThe metabolism of Minaprine can be decreased when combined with Clozapine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clozapine.
MirabegronMirabegron may increase the QTc-prolonging activities of Clozapine.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Clozapine.
MirtazapineClozapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Clozapine.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Clozapine.
MitomycinThe risk or severity of adverse effects can be increased when Mitomycin is combined with Clozapine.
MitotaneThe serum concentration of Clozapine can be decreased when it is combined with Mitotane.
MitoxantroneThe risk or severity of adverse effects can be increased when Mitoxantrone is combined with Clozapine.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Clozapine.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Clozapine.
ModafinilThe serum concentration of Clozapine can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the QTc-prolonging activities of Clozapine.
MolindoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Molindone.
MorphineThe serum concentration of Clozapine can be increased when it is combined with Morphine.
MorphineThe metabolism of Morphine can be decreased when combined with Clozapine.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Clozapine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Clozapine.
NabiloneThe risk or severity of adverse effects can be increased when Clozapine is combined with Nabilone.
NafcillinThe serum concentration of Clozapine can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Clozapine is combined with Nalbuphine.
NaltrexoneThe serum concentration of Clozapine can be increased when it is combined with Naltrexone.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Clozapine.
NaringeninThe serum concentration of Clozapine can be increased when it is combined with Naringenin.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Clozapine.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Clozapine.
NefazodoneThe metabolism of Clozapine can be decreased when combined with Nefazodone.
NelarabineThe risk or severity of adverse effects can be increased when Nelarabine is combined with Clozapine.
NelfinavirNelfinavir may increase the QTc-prolonging activities of Clozapine.
NeostigmineThe serum concentration of Clozapine can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Clozapine can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Clozapine.
NevirapineThe serum concentration of Clozapine can be decreased when it is combined with Nevirapine.
NevirapineThe metabolism of Nevirapine can be decreased when combined with Clozapine.
NicardipineNicardipine may increase the QTc-prolonging activities of Clozapine.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Clozapine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Clozapine.
NicotineThe metabolism of Nicotine can be decreased when combined with Clozapine.
NifedipineThe serum concentration of Clozapine can be decreased when it is combined with Nifedipine.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Clozapine.
NilotinibThe risk or severity of adverse effects can be increased when Nilotinib is combined with Clozapine.
NilotinibClozapine may increase the QTc-prolonging activities of Nilotinib.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Clozapine.
NisoldipineThe serum concentration of Clozapine can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Clozapine can be increased when it is combined with Nitrazepam.
NitrazepamThe risk or severity of adverse effects can be increased when Clozapine is combined with Nitrazepam.
NitrendipineThe serum concentration of Clozapine can be increased when it is combined with Nitrendipine.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Clozapine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Clozapine is combined with Nitrous oxide.
NorethisteroneThe serum concentration of Clozapine can be decreased when it is combined with Norethisterone.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Clozapine.
NormethadoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Clozapine.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Clozapine.
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Clozapine.
OctreotideOctreotide may increase the QTc-prolonging activities of Clozapine.
OfloxacinClozapine may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Olanzapine.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Clozapine.
OlaparibThe risk or severity of adverse effects can be increased when Olaparib is combined with Clozapine.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Clozapine.
OlopatadineThe risk or severity of adverse effects can be increased when Clozapine is combined with Olopatadine.
OmeprazoleThe serum concentration of Clozapine can be decreased when it is combined with Omeprazole.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Clozapine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Clozapine.
OpiumThe risk or severity of adverse effects can be increased when Clozapine is combined with Opium.
OrphenadrineClozapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Clozapine.
OsanetantThe risk or severity of adverse effects can be increased when Clozapine is combined with Osanetant.
OsimertinibThe serum concentration of Clozapine can be increased when it is combined with Osimertinib.
OxaliplatinThe risk or severity of adverse effects can be increased when Oxaliplatin is combined with Clozapine.
OxazepamThe risk or severity of adverse effects can be increased when Clozapine is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Clozapine is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Oxybuprocaine.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Clozapine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clozapine.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Clozapine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Clozapine.
OxytocinOxytocin may increase the QTc-prolonging activities of Clozapine.
P-NitrophenolThe serum concentration of Clozapine can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Clozapine.
PalbociclibThe risk or severity of adverse effects can be increased when Palbociclib is combined with Clozapine.
PaliperidoneClozapine may increase the QTc-prolonging activities of Paliperidone.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clozapine.
Palmitic AcidThe serum concentration of Clozapine can be increased when it is combined with Palmitic Acid.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Clozapine.
PanobinostatClozapine may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Clozapine can be decreased when combined with Panobinostat.
PantoprazoleThe serum concentration of Clozapine can be increased when it is combined with Pantoprazole.
ParaldehydeClozapine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Clozapine.
ParoxetineThe risk or severity of adverse effects can be increased when Clozapine is combined with Paroxetine.
PasireotidePasireotide may increase the QTc-prolonging activities of Clozapine.
PazopanibPazopanib may increase the QTc-prolonging activities of Clozapine.
PazopanibThe metabolism of Pazopanib can be decreased when combined with Clozapine.
Peginterferon alfa-2aThe risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Clozapine.
Peginterferon alfa-2bThe risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Clozapine.
PemetrexedThe risk or severity of adverse effects can be increased when Pemetrexed is combined with Clozapine.
PentamidinePentamidine may increase the QTc-prolonging activities of Clozapine.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Clozapine.
PentazocineThe risk or severity of adverse effects can be increased when Clozapine is combined with Pentazocine.
PentobarbitalThe serum concentration of Clozapine can be decreased when it is combined with Pentobarbital.
PentobarbitalThe risk or severity of adverse effects can be increased when Clozapine is combined with Pentobarbital.
PentostatinThe risk or severity of adverse effects can be increased when Pentostatin is combined with Clozapine.
PerampanelThe risk or severity of adverse effects can be increased when Clozapine is combined with Perampanel.
PerflutrenClozapine may increase the QTc-prolonging activities of Perflutren.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Clozapine.
PerindoprilThe serum concentration of Clozapine can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Clozapine is combined with Perospirone.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Clozapine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Clozapine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Clozapine.
PethidineThe metabolism of Pethidine can be decreased when combined with Clozapine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Clozapine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Clozapine.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Clozapine.
PhenobarbitalThe serum concentration of Clozapine can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe risk or severity of adverse effects can be increased when Clozapine is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Clozapine is combined with Phenoxyethanol.
PhentermineClozapine may decrease the stimulatory activities of Phentermine.
PhenytoinThe serum concentration of Clozapine can be decreased when it is combined with Phenytoin.
PhenytoinThe risk or severity of adverse effects can be increased when Clozapine is combined with Phenytoin.
PimozideClozapine may increase the QTc-prolonging activities of Pimozide.
PimozideThe serum concentration of Clozapine can be increased when it is combined with Pimozide.
PindololThe metabolism of Pindolol can be decreased when combined with Clozapine.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Clozapine.
PioglitazoneThe metabolism of Clozapine can be decreased when combined with Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Pipamperone.
PiperazineThe metabolism of Piperazine can be decreased when combined with Clozapine.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Clozapine.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Clozapine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Clozapine.
PizotifenThe risk or severity of adverse effects can be increased when Clozapine is combined with Pizotifen.
Platelet Activating FactorThe serum concentration of Clozapine can be decreased when it is combined with Platelet Activating Factor.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Clozapine.
PonatinibThe risk or severity of adverse effects can be increased when Ponatinib is combined with Clozapine.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Clozapine.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Clozapine.
PramipexoleClozapine may increase the sedative activities of Pramipexole.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Clozapine.
PramocaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Pramocaine.
PravastatinThe serum concentration of Clozapine can be increased when it is combined with Pravastatin.
PrazepamThe risk or severity of adverse effects can be increased when Clozapine is combined with Prazepam.
PrazosinThe serum concentration of Clozapine can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Clozapine can be increased when it is combined with Prednisone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Clozapine.
PrilocaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Prilocaine.
PrimaquineClozapine may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe serum concentration of Clozapine can be decreased when it is combined with Primidone.
PrimidoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Primidone.
ProbenecidThe serum concentration of Clozapine can be increased when it is combined with Probenecid.
ProcainamideClozapine may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Procaine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Clozapine.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Clozapine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clozapine.
ProgesteroneThe serum concentration of Clozapine can be decreased when it is combined with Progesterone.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Clozapine.
PromazineThe metabolism of Clozapine can be decreased when combined with Promazine.
PromazineThe risk or severity of adverse effects can be increased when Clozapine is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Clozapine.
PromethazineThe metabolism of Promethazine can be decreased when combined with Clozapine.
PropafenoneThe serum concentration of Clozapine can be increased when it is combined with Propafenone.
PropafenoneThe metabolism of Propafenone can be decreased when combined with Clozapine.
ProparacaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Proparacaine.
PropofolPropofol may increase the QTc-prolonging activities of Clozapine.
PropofolThe metabolism of Propofol can be decreased when combined with Clozapine.
PropoxycaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Propoxycaine.
PropranololThe serum concentration of Clozapine can be increased when it is combined with Propranolol.
PropranololThe metabolism of Propranolol can be decreased when combined with Clozapine.
PropylthiouracilThe risk or severity of adverse effects can be increased when Propylthiouracil is combined with Clozapine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Clozapine.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Clozapine.
PSD502The risk or severity of adverse effects can be increased when Clozapine is combined with PSD502.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Clozapine.
PyrimethamineThe metabolism of Clozapine can be decreased when combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Clozapine is combined with Quazepam.
QuercetinThe serum concentration of Clozapine can be increased when it is combined with Quercetin.
QuetiapineClozapine may increase the QTc-prolonging activities of Quetiapine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clozapine.
QuinacrineThe serum concentration of Clozapine can be increased when it is combined with Quinacrine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Clozapine.
QuinidineClozapine may increase the QTc-prolonging activities of Quinidine.
QuinidineThe serum concentration of Clozapine can be increased when it is combined with Quinidine.
QuinineClozapine may increase the QTc-prolonging activities of Quinine.
QuinineThe serum concentration of Clozapine can be increased when it is combined with Quinine.
RabeprazoleThe metabolism of Clozapine can be decreased when combined with Rabeprazole.
RaltitrexedThe risk or severity of adverse effects can be increased when Raltitrexed is combined with Clozapine.
RamelteonThe risk or severity of adverse effects can be increased when Clozapine is combined with Ramelteon.
RanitidineThe serum concentration of Clozapine can be increased when it is combined with Ranitidine.
RanitidineThe metabolism of Ranitidine can be decreased when combined with Clozapine.
RanolazineThe serum concentration of Clozapine can be increased when it is combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Clozapine.
ReboxetineThe serum concentration of Clozapine can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Clozapine can be increased when it is combined with Regorafenib.
RemifentanilThe risk or severity of adverse effects can be increased when Clozapine is combined with Remifentanil.
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Clozapine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clozapine.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Clozapine.
repinotanThe metabolism of repinotan can be decreased when combined with Clozapine.
ReserpineThe serum concentration of Clozapine can be decreased when it is combined with Reserpine.
ReserpineThe risk or severity of adverse effects can be increased when Clozapine is combined with Reserpine.
RifabutinThe serum concentration of Clozapine can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Clozapine can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Clozapine can be decreased when it is combined with Rifapentine.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Clozapine.
RisperidoneRisperidone may increase the QTc-prolonging activities of Clozapine.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Clozapine.
RitonavirRitonavir may increase the QTc-prolonging activities of Clozapine.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Clozapine.
RituximabThe risk or severity of adverse effects can be increased when Rituximab is combined with Clozapine.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Clozapine.
RolapitantThe serum concentration of Clozapine can be increased when it is combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Clozapine is combined with Romifidine.
RopiniroleClozapine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Clozapine can be decreased when combined with Ropinirole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Clozapine.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Clozapine.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Clozapine.
RosiglitazoneThe metabolism of Clozapine can be decreased when combined with Rosiglitazone.
RotigotineClozapine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Clozapine.
RuxolitinibThe risk or severity of adverse effects can be increased when Ruxolitinib is combined with Clozapine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Clozapine is combined with S-Ethylisothiourea.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Clozapine.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Clozapine.
SaquinavirThe serum concentration of Clozapine can be decreased when it is combined with Saquinavir.
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Clozapine.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Clozapine.
ScopolamineThe serum concentration of Clozapine can be increased when it is combined with Scopolamine.
ScopolamineThe risk or severity of adverse effects can be increased when Clozapine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Clozapine is combined with Secobarbital.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Clozapine.
SertindoleThe metabolism of Sertindole can be decreased when combined with Clozapine.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Clozapine.
SertralineThe risk or severity of adverse effects can be increased when Clozapine is combined with Sertraline.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Clozapine.
SevofluraneThe risk or severity of adverse effects can be increased when Clozapine is combined with Sevoflurane.
SildenafilThe metabolism of Clozapine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Clozapine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Clozapine can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Clozapine can be increased when it is combined with Simvastatin.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Clozapine.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Clozapine.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Clozapine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Clozapine is combined with Sodium oxybate.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Clozapine.
SorafenibThe risk or severity of adverse effects can be increased when Sorafenib is combined with Clozapine.
SotalolClozapine may increase the QTc-prolonging activities of Sotalol.
SparteineThe metabolism of Sparteine can be decreased when combined with Clozapine.
SpironolactoneThe serum concentration of Clozapine can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Clozapine can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Clozapine can be increased when it is combined with Staurosporine.
StiripentolThe risk or severity of adverse effects can be increased when Clozapine is combined with Stiripentol.
StreptozocinThe risk or severity of adverse effects can be increased when Streptozocin is combined with Clozapine.
SufentanilThe risk or severity of adverse effects can be increased when Clozapine is combined with Sufentanil.
SulfadiazineThe metabolism of Clozapine can be decreased when combined with Sulfadiazine.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Clozapine.
SulfinpyrazoneThe serum concentration of Clozapine can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleClozapine may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Clozapine can be decreased when combined with Sulfisoxazole.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Clozapine.
SulpirideThe risk or severity of adverse effects can be increased when Clozapine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Clozapine.
SunitinibSunitinib may increase the QTc-prolonging activities of Clozapine.
SuvorexantThe risk or severity of adverse effects can be increased when Clozapine is combined with Suvorexant.
TacrineThe serum concentration of Clozapine can be increased when it is combined with Tacrine.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Clozapine.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Clozapine.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Clozapine.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Clozapine.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Clozapine.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Clozapine.
TasimelteonThe risk or severity of adverse effects can be increased when Clozapine is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Clozapine can be increased when it is combined with Taurocholic Acid.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Clozapine.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Clozapine.
TelaprevirThe metabolism of Clozapine can be decreased when combined with Telaprevir.
TelavancinClozapine may increase the QTc-prolonging activities of Telavancin.
TelithromycinClozapine may increase the QTc-prolonging activities of Telithromycin.
TelmisartanThe serum concentration of Clozapine can be increased when it is combined with Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Clozapine.
TemozolomideThe risk or severity of adverse effects can be increased when Temozolomide is combined with Clozapine.
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Clozapine.
TeniposideThe risk or severity of adverse effects can be increased when Teniposide is combined with Clozapine.
TenofovirThe metabolism of Clozapine can be decreased when combined with Tenofovir.
TerazosinThe serum concentration of Clozapine can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Clozapine can be decreased when combined with Terbinafine.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Clozapine.
TerfenadineThe serum concentration of Clozapine can be increased when it is combined with Terfenadine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Clozapine.
TeriflunomideThe serum concentration of Clozapine can be decreased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Clozapine can be decreased when it is combined with Tesmilifene.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Clozapine.
TestosteroneThe serum concentration of Clozapine can be increased when it is combined with Testosterone.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Clozapine.
TetrabenazineClozapine may increase the QTc-prolonging activities of Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Clozapine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Clozapine is combined with Tetrodotoxin.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Clozapine.
ThalidomideClozapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TheophyllineThe metabolism of Clozapine can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Clozapine is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Clozapine is combined with Thiopental.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Clozapine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Clozapine.
ThiotepaThe risk or severity of adverse effects can be increased when Thiotepa is combined with Clozapine.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Clozapine.
ThiothixeneThe risk or severity of adverse effects can be increased when Clozapine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Clozapine is combined with Tiagabine.
TicagrelorThe serum concentration of Clozapine can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Clozapine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Clozapine is combined with Tiletamine.
TimololThe metabolism of Timolol can be decreased when combined with Clozapine.
TioguanineThe risk or severity of adverse effects can be increased when Tioguanine is combined with Clozapine.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Clozapine.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Clozapine.
TizanidineTizanidine may increase the QTc-prolonging activities of Clozapine.
TizanidineThe risk or severity of adverse effects can be increased when Clozapine is combined with Tizanidine.
TocilizumabThe serum concentration of Clozapine can be decreased when it is combined with Tocilizumab.
TofacitinibThe risk or severity of adverse effects can be increased when Tofacitinib is combined with Clozapine.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Clozapine.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Clozapine.
TolbutamideThe metabolism of Clozapine can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Clozapine is combined with Tolcapone.
TolterodineTolterodine may increase the QTc-prolonging activities of Clozapine.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Clozapine.
TolvaptanThe serum concentration of Clozapine can be increased when it is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Clozapine is combined with Topiramate.
TopotecanThe risk or severity of adverse effects can be increased when Topotecan is combined with Clozapine.
ToremifeneClozapine may increase the QTc-prolonging activities of Toremifene.
TositumomabThe risk or severity of adverse effects can be increased when Tositumomab is combined with Clozapine.
TrabectedinThe risk or severity of adverse effects can be increased when Trabectedin is combined with Clozapine.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Clozapine.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Clozapine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Clozapine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Clozapine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clozapine.
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Clozapine.
TrazodoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Trazodone.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Clozapine.
TriazolamThe risk or severity of adverse effects can be increased when Clozapine is combined with Triazolam.
TrifluoperazineThe serum concentration of Clozapine can be increased when it is combined with Trifluoperazine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Clozapine is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Clozapine can be increased when it is combined with Triflupromazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Clozapine is combined with Triflupromazine.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Clozapine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Clozapine.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Clozapine.
TriprolidineThe risk or severity of adverse effects can be increased when Clozapine is combined with Triprolidine.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Clozapine.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Clozapine.
TroleandomycinThe serum concentration of Clozapine can be increased when it is combined with Troleandomycin.
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Clozapine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Clozapine.
ValsartanThe metabolism of Clozapine can be decreased when combined with Valsartan.
VandetanibClozapine may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Clozapine.
VemurafenibThe serum concentration of Clozapine can be increased when it is combined with Vemurafenib.
VemurafenibClozapine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Clozapine.
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Clozapine.
VerapamilThe metabolism of Clozapine can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Clozapine is combined with Vigabatrin.
VilanterolVilanterol may increase the QTc-prolonging activities of Clozapine.
VilazodoneThe risk or severity of adverse effects can be increased when Clozapine is combined with Vilazodone.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Clozapine.
VinblastineThe risk or severity of adverse effects can be increased when Vinblastine is combined with Clozapine.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Clozapine.
VincristineThe serum concentration of Clozapine can be decreased when it is combined with Vincristine.
VindesineThe risk or severity of adverse effects can be increased when Vindesine is combined with Clozapine.
VinorelbineThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Clozapine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Clozapine.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Clozapine.
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Clozapine.
VorinostatThe risk or severity of adverse effects can be increased when Vorinostat is combined with Clozapine.
VortioxetineThe risk or severity of adverse effects can be increased when Clozapine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Clozapine is combined with Xylazine.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Clozapine.
ZafirlukastThe metabolism of Clozapine can be decreased when combined with Zafirlukast.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Clozapine.
ZaleplonThe risk or severity of adverse effects can be increased when Clozapine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Clozapine is combined with Ziconotide.
ZidovudineThe risk or severity of adverse effects can be increased when Zidovudine is combined with Clozapine.
ZimelidineThe risk or severity of adverse effects can be increased when Clozapine is combined with Zimelidine.
ZimelidineThe serum concentration of Clozapine can be increased when it is combined with Zimelidine.
ZiprasidoneClozapine may increase the QTc-prolonging activities of Ziprasidone.
ZiprasidoneThe metabolism of Clozapine can be decreased when combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Clozapine is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Clozapine.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Clozapine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Clozapine.
ZonisamideThe risk or severity of adverse effects can be increased when Clozapine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Clozapine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Clozapine is combined with Zotepine.
ZuclopenthixolClozapine may increase the QTc-prolonging activities of Zuclopenthixol.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clozapine.
Food Interactions
  • Avoid alcohol.
  • Limit caffeine intake (may reduce clozapine matabolism).
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Green AI, Salomon MS, Brenner MJ, Rawlins K: Treatment of schizophrenia and comorbid substance use disorder. Curr Drug Targets CNS Neurol Disord. 2002 Apr;1(2):129-39. [PubMed:12769622 ]
  2. Weizman T, Pick CG, Backer MM, Rigai T, Bloch M, Schreiber S: The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms. Eur J Pharmacol. 2003 Oct 8;478(2-3):155-9. [PubMed:14575800 ]
  3. Young RM, Lawford BR, Barnes M, Burton SC, Ritchie T, Ward WK, Noble EP: Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br J Psychiatry. 2004 Aug;185:147-51. [PubMed:15286066 ]
  4. Stonehouse AH, Jones FS: Bromocriptine and clozapine regulate dopamine 2 receptor gene expression in the mouse striatum. J Mol Neurosci. 2005;25(1):29-36. [PubMed:15781964 ]
  5. Takano A, Suhara T, Kusumi I, Takahashi Y, Asai Y, Yasuno F, Ichimiya T, Inoue M, Sudo Y, Koyama T: Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Jan;30(1):75-81. Epub 2005 Jul 22. [PubMed:16040180 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Goldstein JM: Quetiapine fumarate (Seroquel): a new atypical antipsychotic. Drugs Today (Barc). 1999 Mar;35(3):193-210. [PubMed:12973385 ]
  2. McDonald LM, Moran PM, Vythelingum GN, Joseph MH, Stephenson JD, Gray JA: Enhancement of latent inhibition by two 5-HT2A receptor antagonists only when given at both pre-exposure and conditioning. Psychopharmacology (Berl). 2003 Sep;169(3-4):321-31. Epub 2002 Aug 9. [PubMed:14530903 ]
  3. Broderick PA, Hope O, Okonji C, Rahni DN, Zhou Y: Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):157-71. [PubMed:14687870 ]
  4. Heiser P, Schulte E, Hausmann C, Becker R, Remschmidt H, Krieg JC, Vedder H: Effects of clozapine and its metabolites on the 5-HT2 receptor system in cortical and hippocampal cells in vitro. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):297-302. [PubMed:14751426 ]
  5. Reist C, Mazzanti C, Vu R, Fujimoto K, Goldman D: Inter-relationships of intermediate phenotypes for serotonin function, impulsivity, and a 5-HT2A candidate allele: His452Tyr. Mol Psychiatry. 2004 Sep;9(9):871-8. [PubMed:15037867 ]
  6. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Zhao AL, Zhao JP, Zhang YH, Xue ZM, Chen JD, Chen XG: Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. Int J Neurosci. 2005 Nov;115(11):1539-47. [PubMed:16223700 ]
  3. Nakane M, Cowart MD, Hsieh GC, Miller L, Uchic ME, Chang R, Terranova MA, Donnelly-Roberts DL, Namovic MT, Miller TR, Wetter JM, Marsh K, Stewart AO, Brioni JD, Moreland RB: 2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist. Neuropharmacology. 2005 Jul;49(1):112-21. Epub 2005 Apr 1. [PubMed:15992586 ]
  4. Kuballa G, Nowak P, Labus L, Bortel A, Dabrowska J, Swoboda M, Kwiecinski A, Kostrzewa RM, Brus R: Central effects of nafadotride, a dopamine D3 receptor antagonist, in rats. Comparison with haloperidol and clozapine. Pharmacol Rep. 2005 Mar-Apr;57(2):161-9. [PubMed:15886414 ]
  5. Glatt SJ, Faraone SV, Tsuang MT: Schizophrenia is not associated with DRD4 48-base-pair-repeat length or individual alleles: results of a meta-analysis. Biol Psychiatry. 2003 Sep 15;54(6):629-35. [PubMed:13129658 ]
  6. Patel S, Chapman KL, Marston D, Hutson PH, Ragan CI: Pharmacological and functional characterisation of dopamine D4 receptors in the rat retina. Neuropharmacology. 2003 Jun;44(8):1038-46. [PubMed:12763097 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Hagino Y, Watanabe M: Effects of clozapine on the efflux of serotonin and dopamine in the rat brain: the role of 5-HT1A receptors. Can J Physiol Pharmacol. 2002 Dec;80(12):1158-66. [PubMed:12564641 ]
  2. Chou YH, Halldin C, Farde L: Occupancy of 5-HT1A receptors by clozapine in the primate brain: a PET study. Psychopharmacology (Berl). 2003 Mar;166(3):234-40. Epub 2003 Feb 13. [PubMed:12589516 ]
  3. Newman-Tancredi A, Rivet JM, Cussac D, Touzard M, Chaput C, Marini L, Millan MJ: Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924. Naunyn Schmiedebergs Arch Pharmacol. 2003 Sep;368(3):188-99. Epub 2003 Aug 16. [PubMed:12923612 ]
  4. Zahorodna A, Bobula B, Grzegorzewska M, Tokarski K, Hess G: The influence of repeated administration of clozapine and haloperidol on the effects of the activation of 5-HT(1A), 5-HT(2) and 5-HT(4) receptors in rat frontal cortex. J Physiol Pharmacol. 2004 Jun;55(2):371-9. [PubMed:15213359 ]
  5. Tomic M, Kundakovic M, Butorovic B, Janac B, Andric D, Roglic G, Ignjatovic D, Kostic-Rajacic S: Pharmacological evaluation of selected arylpiperazines with atypical antipsychotic potential. Bioorg Med Chem Lett. 2004 Aug 16;14(16):4263-6. [PubMed:15261283 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
Gene Name:
HTR1E
Uniprot ID:
P28566
Molecular Weight:
41681.57 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Sodhi MS, Airey DC, Lambert W, Burnet PW, Harrison PJ, Sanders-Bush E: A rapid new assay to detect RNA editing reveals antipsychotic-induced changes in serotonin-2C transcripts. Mol Pharmacol. 2005 Sep;68(3):711-9. Epub 2005 May 25. [PubMed:15917433 ]
  2. Navailles S, De Deurwaerdere P, Spampinato U: Clozapine and haloperidol differentially alter the constitutive activity of central serotonin2C receptors in vivo. Biol Psychiatry. 2006 Mar 15;59(6):568-75. Epub 2005 Sep 22. [PubMed:16182256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Roegge CS, Perraut C, Hao X, Levin ED: Histamine H1 receptor involvement in prepulse inhibition and memory function: relevance for the antipsychotic actions of clozapine. Pharmacol Biochem Behav. 2007 Apr;86(4):686-92. Epub 2007 Feb 22. [PubMed:17382376 ]
  3. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues. Displays a significant level of constitutive activity (spontaneous activity in the absence of agonist).
Gene Name:
HRH4
Uniprot ID:
Q9H3N8
Molecular Weight:
44495.375 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Sugata Y, Okano M, Fujiwara T, Matsumoto R, Hattori H, Yamamoto M, Nishibori M, Nishizaki K: Histamine H4 receptor agonists have more activities than H4 agonism in antigen-specific human T-cell responses. Immunology. 2007 Jun;121(2):266-75. Epub 2007 Mar 7. [PubMed:17346280 ]
  3. Smits RA, Lim HD, Stegink B, Bakker RA, de Esch IJ, Leurs R: Characterization of the histamine H4 receptor binding site. Part 1. Synthesis and pharmacological evaluation of dibenzodiazepine derivatives. J Med Chem. 2006 Jul 27;49(15):4512-6. [PubMed:16854056 ]
  4. Adachi N, Liu K, Motoki A, Nishibori M, Arai T: Suppression of ischemia/reperfusion liver injury by histamine H4 receptor stimulation in rats. Eur J Pharmacol. 2006 Aug 21;544(1-3):181-7. Epub 2006 Jun 29. [PubMed:16860312 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Clathrin light chain binding
Specific Function:
Interacts with clathrin light chain A and stimulates clathrin self-assembly and clathrin-mediated endocytosis.
Gene Name:
CALY
Uniprot ID:
Q9NYX4
Molecular Weight:
23433.49 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Brosen K: Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Clin Pharmacokinet. 1995;29 Suppl 1:20-5. [PubMed:8846619 ]
  2. Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. [PubMed:19754423 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Fang J, Coutts RT, McKenna KF, Baker GB: Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch Pharmacol. 1998 Nov;358(5):592-9. [PubMed:9840430 ]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  6. Carrillo JA, Benitez J: Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet. 2000 Aug;39(2):127-53. [PubMed:10976659 ]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Trimethylamine monooxygenase activity
Specific Function:
Involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. It N-oxygenates primary aliphatic alkylamines as well as secondary and tertiary amines. Plays an important role in the metabolism of trimethylamine (TMA), via the production of TMA N-oxide (TMAO). Is also able to perform S-oxidation when acting on sulfide compounds (PubMed:9224773).
Gene Name:
FMO3
Uniprot ID:
P31513
Molecular Weight:
60032.975 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein homodimerization activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1 (By similarity).
Gene Name:
UGT1A4
Uniprot ID:
P22310
Molecular Weight:
60024.535 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9. [PubMed:12031686 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2016 02:15